Pulmonx beats by $0.04, beats on revs; raises FY23 revs outlook
- Reports Q3 (Sep) loss of $0.39 per share, $0.04 better than the FactSet Consensus of ($0.43); revenues rose 30.9% year/year to $17.67 mln vs the $16.67 mln FactSet Consensus.
- Co issues upside guidance for FY23, sees FY23 revs of $67-$68 mln (from $64-$66 mln) vs. $65.95 mln FactSet Consensus.
- Pulmonx also continues to expect total operating expenses for the full year 2023 to fall within the range of $112 million to $114 million, inclusive of approximately $21 million of non-cash stock-based compensation.
- The Company expects gross margin for the full year 2023 to be approximately 74%.
No comments:
Post a Comment